Kriya Therapeutics reports preclinical findings where a single intramuscular dose of its AAV-FGF21 gene therapy extended both health span and lifespan in aged mice. The treatment demonstrates sustained improvements across multiple organ systems, according to published data.
The FDA has chosen **Kriya** to participate in its **PreCheck pilot program**, recognizing the company’s **integrated manufacturing infrastructure**. This selection aims to accelerate the development of Kriya’s **AAV gene therapy pipeline** toward commercialization by streamlining regulatory review processes.
Kriya Therapeutics presents new developments at ASGCT 2026, showcasing progress in its gene therapy platform. The company’s integrated approach combines research and manufacturing to expand access to treatments for common chronic diseases. Presentations focus on advancing scalable and accessible gene therapy solutions.
Kriya Therapeutics names Sachiyo Minegishi as its new Chief Financial Officer. Minegishi brings experience in financial strategy and commercialization from her background in public and private biopharma companies. The appointment aims to strengthen Kriya’s corporate development and financial leadership.
